Understand the source comparison
GHRP-2 Acetate 30s Age Specific Protocol Comparison
30–39 years 100–200mcg 2–3x daily Augment existing endogenous GH pulsatility without suppression HIGH. ACTH co-release significant in reactive HPA axis Optimize for enhancement, not replacement; monitor fasting glucose as cortisol proxy 40–49 years 150–250mcg
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 30–39 years
- 100–200mcg
- 2–3x daily
- Augment existing endogenous GH pulsatility without suppression
- HIGH. ACTH co-release significant in reactive HPA axis
- Optimize for enhancement, not replacement; monitor fasting glucose as cortisol proxy
- 40–49 years
- 150–250mcg
- Restore declining GH amplitude; bridge partial endogenous function
- MODERATE. Some HPA blunting begins; cortisol reactivity individual-dependent
- Balance exogenous support with remaining natural function; insulin sensitivity becomes limiting factor
- 50+ years
- 200–300mcg
- 3–4x daily
- Replace substantially diminished endogenous GH output
- LOW. Blunted adrenal responsiveness reduces ACTH-driven cortisol spikes
- Focus shifts to maximal exogenous GH; desensitization and receptor downregulation primary concerns